title: Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.
abstract: Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.
authors.affiliation: Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Meister
authors.affiliation: Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany.
authors.forename: Sandra
authors.initials: S
authors.lastname: Voss
authors.affiliation: Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Schwabe
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001260:Ataxia Telangiectasia / Q000150:complications / Q000188:drug therapy*; D000079963:Brentuximab Vedotin; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy*; D004854:Herpesvirus 4, Human; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D000069283:Rituximab / Q000008:administration & dosage* / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D011344:Procarbazine; D000069283:Rituximab; D014750:Vincristine; D000079963:Brentuximab Vedotin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Hodgkin lymphoma; ataxia telangiectasia; brentuximab vedotin